US-based medical device firm Luna Health has successfully closed a $23.6 million Series A funding round to accelerate the development of its next-generation insulin patch pump.
The round was led by Vensana Capital with participation from the Swiss Diabetes Venture Fund, Winklevoss Capital, and Ascensia Diabetes Care, reflecting strong investor confidence in diabetes technology innovation.
Funds will support regulatory submissions, clinical trials, scaling up manufacturing, and expanding market access programmes.
The Luna patch pump, designed for individuals with type 1 and type 2 diabetes, integrates with a closed-loop insulin dosing algorithm and is compatible with iCGM systems. It delivers automated doses of rapid-acting insulin during sleep—a period when the company notes over 80% of glucose improvements from automated insulin delivery occur.
Unlike full-time pump therapy, Luna’s cost-effective system targets nighttime glucose control, lowering barriers to adoption while simplifying care. The device is positioned as a more accessible alternative for patients who rely on insulin pens and may be hesitant to use traditional continuous pumps.
Jon Brilliant, Luna Health CFO and co-founder, stated:
"We are incredibly excited and fortunate to partner with Vensana Capital to accelerate bringing to market our products that solve the single largest problem in all of diabetes—nighttime glucose control for pen users."